Bristol-Myers Squibb (BMY) Granted EC Approval for Inrebic (fedratinib) for Adult Patients with Newly Diagnosed & Previously Treated Myelofibrosis
- Stocks decline as interest rate uncertainty, earnings weigh
- ASML slides as Q1 sales fall short but firm still on track for 2025 revenue target
- US dollar weakens as market consolidates gains, but uptrend intact
- Abbott Laboratories (ABT) narrows 2024 earnings guidance, shares slip
- Stocks have priced in much of the 2024 optimism - Wells Fargo
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- ICZOOM Group (IZM) Discloses Request to Withdraw Registration Statement on Form F-1
- Alaska Airlines flights resume after being grounded over aircraft system issue
- Crude Inventory Rose 2.7 Million Barrels Last Week, Says EIA
- Lithium Americas Corp (LAC) Announces Proposed 55M Share Offering
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
- After-hours movers: United Airlines, J.B. Hunt, and more
- Midday movers: Morgan Stanley, UnitedHealth rise; Tesla falls
- Morgan Stanley, UnitedHealth and Bank of America rise premarket; Tesla falls
FDA Approves Bristol-Myers Squibb's (BMY) New Treatment For Adults With Relapsed Or Refractory Large-B-Cell Lymphoma
February 5, 2021 3:05 PM EST(Updated - February 5, 2021 3:06 PM EST)
Today, the U.S. Food and Drug Administration approved Breyanzi (lisocabtagene maraleucel), a cell-based gene therapy to treat adult patients with certain types of large B-cell lymphoma who have not responded to, or who have relapsed after, at least two other types of systemic treatment. Breyanzi, a chimeric antigen receptor (CAR) T cell therapy, is the third gene therapy approved by the FDA for certain types of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma (DLBCL). Breyanzi is not indicated for the treatment of patients with primary central nervous system lymphoma.
"Today's approval represents... More
Bristol-Myers Squibb Co. (BMY) PT Raised to $66 at Truist Securities
February 5, 2021 8:43 AM ESTTruist Securities raised its price target on Bristol-Myers Squibb Co. (NYSE: BMY) to $66.00 (from $65.00) while maintaining a Hold rating.... More
Bristol-Myers Squibb (BMY) Tops Q4 EPS by 5c, Offers FY Guidance
February 4, 2021 7:01 AM ESTBristol-Myers Squibb (NYSE: BMY) reported Q4 EPS of $1.46, $0.05 better than the analyst estimate of $1.41. Revenue for the quarter came in at $11.07 billion versus the consensus estimate of $10.73 billion.
GUIDANCE:
Bristol-Myers Squibb sees FY2021 EPS of $7.35-$7.55, versus the consensus... More